Kraig Biocraft Laboratories Files for Expanded Investment License
Kraig Biocraft Laboratories (OTCMKTS: KBLB) has filed to expand the investment license of its production subsidiary, Prodigy Silk. The move is intended to secure additional capital needed for the next phase of growth in recombinant spider silk production. The company emphasized that this step will support scaling up operations and advancing product development within its biotechnology sector. This filing reflects strategic planning aimed at enhancing manufacturing capabilities and market expansion, potentially strengthening investor confidence as it moves toward commercialization goals.
Tickers: $KBLB
Topics: biotechnology capital raising spider silk production